查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1434672

血管水肿治疗药物市场：按药物类型、给药途径和最终用户划分 - 全球预测 2024-2030

Angioedema Treatment Market by Drugs Type (C1 Esterase Inhibitor, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist), Route of Administration (Injections, Oral), End-User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年血管水肿治疗市场规模为46.9亿美元，预计2024年将达55亿美元，2030年将达到143.2亿美元，复合年增长率为17.28%。

血管性水肿治疗的全球市场

主要市场统计
基准年[2023] 46.9亿美元
预测年份 [2024] 55亿美元
预测年份 [2030] 143.2亿美元
复合年增长率（%） 17.28%
血管性水肿治疗药物市场-IMG1

FPNV定位矩阵

FPNV定位矩阵对于评估血管水肿治疗市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对血管水肿治疗药物市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告在以下方面提供了宝贵的见解：

1-市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2-市场开拓：我们深入研究利润丰厚的新兴市场并分析其在成熟细分市场的渗透率。

3- 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4-竞争力评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5- 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1-血管水肿治疗药物市场的市场规模与预测是多少？

2-在血管水肿治疗药物市场的预测期内，有哪些产品、细分市场、应用和领域需要考虑投资？

3-血管水肿治疗市场的技术趋势和法律规范是什么？

4-血管水肿治疗药物市场主要供应商的市场占有率是多少？

5-进入血管性水肿治疗市场的适当型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 遗传性血管性水肿 (HAE) 病例呈上升趋势
      • 加大力度提高意识层级
      • 疾病相关基因突变的发生率增加
    • 抑制因素
      • 血管性水肿的误诊
    • 机会
      • 政府努力促进更快的诊断并提供最佳的护理标准
      • 开发治疗遗传性血管水肿疾病的先进治疗方法
    • 任务
      • 用于治疗的药物成本较高
  • 市场区隔分析
  • 市场趋势分析
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范

第六章依药物类型分類的血管性水肿治疗药物市场

  • C1酯酶抑制剂
    • 贝里纳托
    • 新升
    • 飞加尔达
    • 勒科内斯特
  • 激肽释放酶抑制剂
    • 卡尔维特尔
  • 选择性缓激肽 B2 受体拮抗
    • 非拉齐尔

第七章血管水肿治疗药物市场：依给药途径

  • 注射
  • 口服

第八章血管水肿治疗药物市场：依最终用户分类

  • 诊所
  • 医院
  • 调查机构

第九章北美和南美血管水肿治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太血管水肿治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲血管性水肿治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争形势

  • FPNV定位矩阵
  • 市场占有率分析：主要企业
  • 主要企业竞争情境分析

第13章竞争产品组合

  • 主要公司简介
    • Adverum Biotechnologies, Inc.
    • AMBOSS GmbH
    • Apotex Corp.
    • Attune Pharmaceuticals, Inc.
    • BioCryst Pharmaceuticals, Inc.
    • Cipla USA Inc.
    • CSL Behring GmbH
    • Fresenius Kabi USA, LLC
    • Ionis Pharmaceuticals, Inc.
    • KalVista Pharmaceuticals, Inc.
    • Lecturio GmbH
    • Merck & Co., Inc.
    • Pharming Group NV
    • Sanofi-Aventis Groupe SA
    • Slayback Pharma LLC
    • Takeda Pharmaceutical Company Limited
    • Viropharma Biologics LLC
  • 主要产品系列

第十四章附录

  • 讨论指南
  • 关于许可证和定价
Product Code: MRR-436901066227

[183 Pages Report] The Angioedema Treatment Market size was estimated at USD 4.69 billion in 2023 and expected to reach USD 5.50 billion in 2024, at a CAGR 17.28% to reach USD 14.32 billion by 2030.

Global Angioedema Treatment Market

KEY MARKET STATISTICS
Base Year [2023] USD 4.69 billion
Estimated Year [2024] USD 5.50 billion
Forecast Year [2030] USD 14.32 billion
CAGR (%) 17.28%
Angioedema Treatment Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Angioedema Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Angioedema Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Angioedema Treatment Market, highlighting leading vendors and their innovative profiles. These include Adverum Biotechnologies, Inc., AMBOSS GmbH, Apotex Corp., Attune Pharmaceuticals, Inc., BioCryst Pharmaceuticals, Inc., Cipla USA Inc., CSL Behring GmbH, Fresenius Kabi USA, LLC, Ionis Pharmaceuticals, Inc., KalVista Pharmaceuticals, Inc., Lecturio GmbH, Merck & Co., Inc., Pharming Group N.V., Sanofi-Aventis Groupe S.A., Slayback Pharma LLC, Takeda Pharmaceutical Company Limited, and Viropharma Biologics LLC.

Market Segmentation & Coverage

This research report categorizes the Angioedema Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drugs Type
    • C1 Esterase Inhibitor
      • Berinert
      • Cinryze
      • Haegarda
      • Ruconest
    • Kallikrein Inhibitor
      • Kalbitor
    • Selective Bradykinin B2 Receptor Antagonist
      • Firazyr
  • Route of Administration
    • Injections
    • Oral
  • End-User
    • Clinics
    • Hospitals
    • Research Organizations
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Angioedema Treatment Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Angioedema Treatment Market?

3. What are the technology trends and regulatory frameworks in the Angioedema Treatment Market?

4. What is the market share of the leading vendors in the Angioedema Treatment Market?

5. Which modes and strategic moves are suitable for entering the Angioedema Treatment Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Angioedema Treatment Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing cases of hereditary angioedema (HAE)
      • 5.1.1.2. Growing initiatives for improving awareness levels among the population
      • 5.1.1.3. Rising incidence of disease-related genetic mutations
    • 5.1.2. Restraints
      • 5.1.2.1. Misdiagnosis of angioedema
    • 5.1.3. Opportunities
      • 5.1.3.1. Government initiatives to facilitate faster diagnosis and provide optimal standards of treatment
      • 5.1.3.2. Development of advance therapeutics for hereditary angioedema disorders treatment
    • 5.1.4. Challenges
      • 5.1.4.1. High cost of the drugs used for treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Angioedema Treatment Market, by Drugs Type

  • 6.1. Introduction
  • 6.2. C1 Esterase Inhibitor
    • 6.3.1. Berinert
    • 6.3.2. Cinryze
    • 6.3.3. Haegarda
    • 6.3.4. Ruconest
  • 6.3. Kallikrein Inhibitor
    • 6.4.1. Kalbitor
  • 6.4. Selective Bradykinin B2 Receptor Antagonist
    • 6.5.1. Firazyr

7. Angioedema Treatment Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Injections
  • 7.3. Oral

8. Angioedema Treatment Market, by End-User

  • 8.1. Introduction
  • 8.2. Clinics
  • 8.3. Hospitals
  • 8.4. Research Organizations

9. Americas Angioedema Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Angioedema Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Angioedema Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Adverum Biotechnologies, Inc.
    • 13.1.2. AMBOSS GmbH
    • 13.1.3. Apotex Corp.
    • 13.1.4. Attune Pharmaceuticals, Inc.
    • 13.1.5. BioCryst Pharmaceuticals, Inc.
    • 13.1.6. Cipla USA Inc.
    • 13.1.7. CSL Behring GmbH
    • 13.1.8. Fresenius Kabi USA, LLC
    • 13.1.9. Ionis Pharmaceuticals, Inc.
    • 13.1.10. KalVista Pharmaceuticals, Inc.
    • 13.1.11. Lecturio GmbH
    • 13.1.12. Merck & Co., Inc.
    • 13.1.13. Pharming Group N.V.
    • 13.1.14. Sanofi-Aventis Groupe S.A.
    • 13.1.15. Slayback Pharma LLC
    • 13.1.16. Takeda Pharmaceutical Company Limited
    • 13.1.17. Viropharma Biologics LLC
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. ANGIOEDEMA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. ANGIOEDEMA TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ANGIOEDEMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ANGIOEDEMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ANGIOEDEMA TREATMENT MARKET DYNAMICS
  • FIGURE 7. ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2023 VS 2030 (%)
  • FIGURE 8. ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 10. ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 12. ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ANGIOEDEMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. ANGIOEDEMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ANGIOEDEMA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 8. ANGIOEDEMA TREATMENT MARKET SIZE, BY BERINERT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. ANGIOEDEMA TREATMENT MARKET SIZE, BY CINRYZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ANGIOEDEMA TREATMENT MARKET SIZE, BY HAEGARDA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. ANGIOEDEMA TREATMENT MARKET SIZE, BY RUCONEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 14. ANGIOEDEMA TREATMENT MARKET SIZE, BY KALBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 17. ANGIOEDEMA TREATMENT MARKET SIZE, BY FIRAZYR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 19. ANGIOEDEMA TREATMENT MARKET SIZE, BY INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. ANGIOEDEMA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. ANGIOEDEMA TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. ANGIOEDEMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. ANGIOEDEMA TREATMENT MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 85. INDIA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 86. INDIA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. INDIA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. INDONESIA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 90. INDONESIA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 91. INDONESIA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 92. INDONESIA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. INDONESIA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. JAPAN ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. JAPAN ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 96. JAPAN ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 97. JAPAN ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 98. JAPAN ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. JAPAN ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. MALAYSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. MALAYSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 102. MALAYSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 103. MALAYSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 104. MALAYSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. MALAYSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. PHILIPPINES ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. PHILIPPINES ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 108. PHILIPPINES ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 109. PHILIPPINES ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 110. PHILIPPINES ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. PHILIPPINES ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. SINGAPORE ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. SINGAPORE ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 114. SINGAPORE ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 115. SINGAPORE ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 116. SINGAPORE ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. SINGAPORE ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. SOUTH KOREA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. SOUTH KOREA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 120. SOUTH KOREA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 121. SOUTH KOREA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH KOREA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH KOREA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. TAIWAN ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. TAIWAN ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 126. TAIWAN ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 127. TAIWAN ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 128. TAIWAN ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. TAIWAN ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. THAILAND ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. THAILAND ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 132. THAILAND ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 133. THAILAND ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 134. THAILAND ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. THAILAND ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. VIETNAM ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. VIETNAM ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 138. VIETNAM ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 139. VIETNAM ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 140. VIETNAM ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. VIETNAM ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 149. DENMARK ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. DENMARK ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 151. DENMARK ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 152. DENMARK ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 153. DENMARK ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. DENMARK ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. EGYPT ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. EGYPT ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 157. EGYPT ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 158. EGYPT ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 159. EGYPT ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. EGYPT ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 161. FINLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. FINLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 163. FINLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 164. FINLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 165. FINLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. FINLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. FRANCE ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. FRANCE ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 169. FRANCE ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 170. FRANCE ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 171. FRANCE ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. FRANCE ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 175. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 176. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 177. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. ISRAEL ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. ISRAEL ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 181. ISRAEL ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 182. ISRAEL ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 183. ISRAEL ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. ISRAEL ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. ITALY ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. ITALY ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 187. ITALY ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 188. ITALY ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 189. ITALY ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. ITALY ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 191. NETHERLANDS ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. NETHERLANDS ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 193. NETHERLANDS ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 194. NETHERLANDS ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 195. NETHERLANDS ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 196. NETHERLANDS ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 197. NIGERIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. NIGERIA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 199. NIGERIA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 200. NIGERIA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 201. NIGERIA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 202. NIGERIA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 203. NORWAY ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. NORWAY ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 205. NORWAY ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 206. NORWAY ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 207. NORWAY ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. NORWAY ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 209. POLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. POLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 211. POLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 212. POLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 213. POLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 214. POLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 215. QATAR ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. QATAR ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 217. QATAR ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 218. QATAR ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 219. QATAR ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 220. QATAR ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 221. RUSSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. RUSSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 223. RUSSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 224. RUSSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 225. RUSSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 226. RUSSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 227. SAUDI ARABIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. SAUDI ARABIA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 229. SAUDI ARABIA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 230. SAUDI ARABIA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 231. SAUDI ARABIA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 232. SAUDI ARABIA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 233. SOUTH AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. SOUTH AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 235. SOUTH AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 236. SOUTH AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 237. SOUTH AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 239. SPAIN ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. SPAIN ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 241. SPAIN ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 242. SPAIN ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 243. SPAIN ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 244. SPAIN ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 245. SWEDEN ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. SWEDEN ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 247. SWEDEN ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 248. SWEDEN ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 249. SWEDEN ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 250. SWEDEN ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 251. SWITZERLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. SWITZERLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 253. SWITZERLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 254. SWITZERLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 255. SWITZERLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 256. SWITZERLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 257. TURKEY ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. TURKEY ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 259. TURKEY ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 260. TURKEY ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 261. TURKEY ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 262. TURKEY ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 263. UNITED ARAB EMIRATES ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. UNITED ARAB EMIRATES ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 265. UNITED ARAB EMIRATES ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 266. UNITED ARAB EMIRATES ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 267. UNITED ARAB EMIRATES ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 268. UNITED ARAB EMIRATES ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 269. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 275. ANGIOEDEMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 276. ANGIOEDEMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 277. ANGIOEDEMA TREATMENT MARKET LICENSE & PRICING